The CoVInov project is a research and technological development project that aims to identify drugs, which are already known and approved for use in humans, having a potential antiviral effect, specifically to combat SARS-CoV2.

There are numerous substances approved for use in humans and, at the same time, there is knowledge about their toxicological and safety profile. This prior knowledge facilitates the faster preclinical and clinical development of a treatment for COVID-19.

The project makes use of repositioning techniques, based on targets and therapeutic classes with proven action in the inhibition of SARSCoV and MERS-CoV. The repositioning study is based on the assessment of viral cytopathic effect in two in vitro screenings, an initial screening for alpha (HcoV-229E) and betacoronaviruses (HcoV-OC43), and another confirmatory screening for SARS-CoV-2.

Find out more on the Project Fact Sheet.